Design Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | — | — | — |
| Research and development | $59.1M | $44.4M | $57.1M | $48.6M | $24.8M |
| Operating expenses | $79.5M | $62.4M | $78.2M | $67.6M | $35.8M |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | -$35.5M |
| Balance Sheet | |||||
| Cash and equivalents | $16.9M | $22.6M | $21.2M | $26.5M | $298.6M |
| Current assets | $223.8M | $248.0M | $284.6M | $335.1M | $385.4M |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M |
| Current liabilities | $13.1M | $8.5M | $9.6M | $10.8M | $5.3M |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M |
| Stockholders' equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M |
| Depreciation and amortization | $622,000 | $596,000 | $537,000 | $406,000 | $129,000 |
| Stock-based compensation | $14.5M | $13.1M | $13.1M | $10.9M | $4.7M |
| Capital expenditure | $193,000 | $340,000 | $256,000 | $918,000 | $1.5M |
| Free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M | -$30.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 62.5M · Free float 49.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.